Everything You Need to Know About Leqembi Maintenance and Medicare
After Leqembi removes amyloid plaques from the brain, treatment isn't over. The brain continues to produce beta-amyloid every day, and in Alzheimer's disease a small amount escapes the brain's natural clearance systems. Without continued treatment, these molecules can gradually accumulate again, forming toxic oligomers, protofibrils, and eventually new plaques. This article explains why maintenance therapy is essential after the initial 18 months of Leqembi, compares monthly IV infusions with the FDA-approved IQLIK® self-injection, and provides a practical guide to Medicare Part B and Part D coverage, specialty pharmacies, formularies, prior authorization, and out-of-pocket costs so you can make informed decisions about your long-term treatment options.
Medicare Advantage Isn't Always an Advantage for Alzheimer's
Choosing the right Medicare coverage can have a major impact on Alzheimer's treatment. While Medicare Advantage plans often offer lower premiums and extra benefits, they may also require prior authorizations, network restrictions, and additional approvals that can delay time-sensitive therapies such as Leqembi and Kisunla. Learn why many Alzheimer's specialists recommend Original Medicare with a Medigap supplement for patients who need access to advanced neurological care.